nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—ADORA2A—NGF-independant TRKA activation—NTRK2—malignant glioma	0.0623	0.144	CbGpPWpGaD
Regadenoson—ADORA2A—Activation of TRKA receptors—NTRK2—malignant glioma	0.0538	0.124	CbGpPWpGaD
Regadenoson—ADORA2A—NGF-independant TRKA activation—NTRK1—malignant glioma	0.0508	0.117	CbGpPWpGaD
Regadenoson—ADORA2A—Activation of TRKA receptors—NTRK1—malignant glioma	0.0439	0.101	CbGpPWpGaD
Regadenoson—Haemorrhage intracranial—Temozolomide—malignant glioma	0.0267	0.0516	CcSEcCtD
Regadenoson—Adenosine monophosphate—PIM1—malignant glioma	0.0238	0.488	CrCbGaD
Regadenoson—Altered state of consciousness—Temozolomide—malignant glioma	0.0237	0.0458	CcSEcCtD
Regadenoson—Faecal incontinence—Carmustine—malignant glioma	0.0224	0.0434	CcSEcCtD
Regadenoson—Faecal incontinence—Temozolomide—malignant glioma	0.0217	0.0419	CcSEcCtD
Regadenoson—Transient ischaemic attack—Temozolomide—malignant glioma	0.0217	0.0419	CcSEcCtD
Regadenoson—Adenosine triphosphate—ACVR1—malignant glioma	0.0175	0.36	CrCbGaD
Regadenoson—Injection site pain—Carmustine—malignant glioma	0.0139	0.0268	CcSEcCtD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—FLT1—malignant glioma	0.0134	0.0308	CbGpPWpGaD
Regadenoson—ADORA2A—Monoamine Transport—SLC6A3—malignant glioma	0.0129	0.0298	CbGpPWpGaD
Regadenoson—Musculoskeletal pain—Temozolomide—malignant glioma	0.0111	0.0214	CcSEcCtD
Regadenoson—Depressed level of consciousness—Carmustine—malignant glioma	0.0109	0.0211	CcSEcCtD
Regadenoson—Depressed level of consciousness—Temozolomide—malignant glioma	0.0106	0.0204	CcSEcCtD
Regadenoson—Eye pain—Carmustine—malignant glioma	0.00911	0.0176	CcSEcCtD
Regadenoson—Eye pain—Temozolomide—malignant glioma	0.0088	0.017	CcSEcCtD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—KDR—malignant glioma	0.00772	0.0178	CbGpPWpGaD
Regadenoson—Adenosine triphosphate—AKT1—malignant glioma	0.00739	0.152	CrCbGaD
Regadenoson—ADORA2A—Circadian rythm related genes—NTRK3—malignant glioma	0.00726	0.0167	CbGpPWpGaD
Regadenoson—Abdominal distension—Temozolomide—malignant glioma	0.00692	0.0134	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Other—CXCR3—malignant glioma	0.00628	0.0145	CbGpPWpGaD
Regadenoson—Renal failure—Carmustine—malignant glioma	0.00623	0.012	CcSEcCtD
Regadenoson—Hypoaesthesia—Carmustine—malignant glioma	0.00566	0.0109	CcSEcCtD
Regadenoson—Connective tissue disorder—Carmustine—malignant glioma	0.00559	0.0108	CcSEcCtD
Regadenoson—Hypoaesthesia—Temozolomide—malignant glioma	0.00547	0.0106	CcSEcCtD
Regadenoson—Connective tissue disorder—Temozolomide—malignant glioma	0.0054	0.0104	CcSEcCtD
Regadenoson—Eye disorder—Carmustine—malignant glioma	0.00532	0.0103	CcSEcCtD
Regadenoson—Flushing—Carmustine—malignant glioma	0.00528	0.0102	CcSEcCtD
Regadenoson—ADORA2A—Monoamine Transport—IL1B—malignant glioma	0.00527	0.0122	CbGpPWpGaD
Regadenoson—Eye disorder—Temozolomide—malignant glioma	0.00514	0.00993	CcSEcCtD
Regadenoson—Tinnitus—Temozolomide—malignant glioma	0.00513	0.0099	CcSEcCtD
Regadenoson—Flushing—Temozolomide—malignant glioma	0.0051	0.00986	CcSEcCtD
Regadenoson—Cardiac disorder—Temozolomide—malignant glioma	0.0051	0.00986	CcSEcCtD
Regadenoson—Angiopathy—Temozolomide—malignant glioma	0.00499	0.00964	CcSEcCtD
Regadenoson—Mental disorder—Carmustine—malignant glioma	0.00498	0.00963	CcSEcCtD
Regadenoson—Immune system disorder—Temozolomide—malignant glioma	0.00497	0.0096	CcSEcCtD
Regadenoson—Mediastinal disorder—Temozolomide—malignant glioma	0.00496	0.00957	CcSEcCtD
Regadenoson—Erythema—Carmustine—malignant glioma	0.00495	0.00957	CcSEcCtD
Regadenoson—Mental disorder—Temozolomide—malignant glioma	0.00482	0.00931	CcSEcCtD
Regadenoson—Erythema—Temozolomide—malignant glioma	0.00479	0.00925	CcSEcCtD
Regadenoson—Dysgeusia—Temozolomide—malignant glioma	0.00469	0.00906	CcSEcCtD
Regadenoson—Vision blurred—Carmustine—malignant glioma	0.00467	0.00902	CcSEcCtD
Regadenoson—Tremor—Carmustine—malignant glioma	0.00464	0.00897	CcSEcCtD
Regadenoson—Vision blurred—Temozolomide—malignant glioma	0.00451	0.00872	CcSEcCtD
Regadenoson—Tremor—Temozolomide—malignant glioma	0.00448	0.00866	CcSEcCtD
Regadenoson—Ill-defined disorder—Temozolomide—malignant glioma	0.00444	0.00858	CcSEcCtD
Regadenoson—Angioedema—Temozolomide—malignant glioma	0.00437	0.00845	CcSEcCtD
Regadenoson—Malaise—Temozolomide—malignant glioma	0.00432	0.00834	CcSEcCtD
Regadenoson—Convulsion—Carmustine—malignant glioma	0.00429	0.00829	CcSEcCtD
Regadenoson—Hypertension—Carmustine—malignant glioma	0.00428	0.00826	CcSEcCtD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—malignant glioma	0.00425	0.0098	CbGpPWpGaD
Regadenoson—Palpitations—Temozolomide—malignant glioma	0.00423	0.00817	CcSEcCtD
Regadenoson—Myalgia—Carmustine—malignant glioma	0.00422	0.00815	CcSEcCtD
Regadenoson—Chest pain—Carmustine—malignant glioma	0.00422	0.00815	CcSEcCtD
Regadenoson—Anxiety—Carmustine—malignant glioma	0.0042	0.00812	CcSEcCtD
Regadenoson—Cough—Temozolomide—malignant glioma	0.00418	0.00807	CcSEcCtD
Regadenoson—Convulsion—Temozolomide—malignant glioma	0.00415	0.00801	CcSEcCtD
Regadenoson—Hypertension—Temozolomide—malignant glioma	0.00413	0.00798	CcSEcCtD
Regadenoson—Arthralgia—Temozolomide—malignant glioma	0.00407	0.00787	CcSEcCtD
Regadenoson—Myalgia—Temozolomide—malignant glioma	0.00407	0.00787	CcSEcCtD
Regadenoson—Anxiety—Temozolomide—malignant glioma	0.00406	0.00785	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00405	0.00782	CcSEcCtD
Regadenoson—Discomfort—Temozolomide—malignant glioma	0.00403	0.00778	CcSEcCtD
Regadenoson—Tachycardia—Carmustine—malignant glioma	0.00394	0.00762	CcSEcCtD
Regadenoson—Anaphylactic shock—Temozolomide—malignant glioma	0.00391	0.00755	CcSEcCtD
Regadenoson—Nervous system disorder—Temozolomide—malignant glioma	0.00383	0.0074	CcSEcCtD
Regadenoson—ADORA2A—Monoamine Transport—TNF—malignant glioma	0.00383	0.00882	CbGpPWpGaD
Regadenoson—Skin disorder—Temozolomide—malignant glioma	0.00379	0.00733	CcSEcCtD
Regadenoson—Hypotension—Carmustine—malignant glioma	0.00378	0.0073	CcSEcCtD
Regadenoson—Hyperhidrosis—Temozolomide—malignant glioma	0.00378	0.0073	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—PML—malignant glioma	0.00372	0.00857	CbGpPWpGaD
Regadenoson—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00368	0.00712	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—CCR4—malignant glioma	0.00367	0.00847	CbGpPWpGaD
Regadenoson—Insomnia—Carmustine—malignant glioma	0.00366	0.00706	CcSEcCtD
Regadenoson—Paraesthesia—Carmustine—malignant glioma	0.00363	0.00701	CcSEcCtD
Regadenoson—Dyspnoea—Carmustine—malignant glioma	0.0036	0.00696	CcSEcCtD
Regadenoson—Somnolence—Carmustine—malignant glioma	0.00359	0.00694	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00356	0.00688	CcSEcCtD
Regadenoson—Insomnia—Temozolomide—malignant glioma	0.00353	0.00683	CcSEcCtD
Regadenoson—Paraesthesia—Temozolomide—malignant glioma	0.00351	0.00678	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Carmustine—malignant glioma	0.00349	0.00674	CcSEcCtD
Regadenoson—Dyspnoea—Temozolomide—malignant glioma	0.00348	0.00673	CcSEcCtD
Regadenoson—Somnolence—Temozolomide—malignant glioma	0.00347	0.00671	CcSEcCtD
Regadenoson—Pain—Carmustine—malignant glioma	0.00346	0.00668	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—TOP2A—malignant glioma	0.0034	0.00784	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00337	0.00652	CcSEcCtD
Regadenoson—Pain—Temozolomide—malignant glioma	0.00334	0.00645	CcSEcCtD
Regadenoson—Feeling abnormal—Carmustine—malignant glioma	0.00333	0.00644	CcSEcCtD
Regadenoson—Gastrointestinal pain—Carmustine—malignant glioma	0.00331	0.00639	CcSEcCtD
Regadenoson—Feeling abnormal—Temozolomide—malignant glioma	0.00322	0.00622	CcSEcCtD
Regadenoson—Abdominal pain—Carmustine—malignant glioma	0.0032	0.00617	CcSEcCtD
Regadenoson—Gastrointestinal pain—Temozolomide—malignant glioma	0.00319	0.00617	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—NTRK2—malignant glioma	0.00318	0.00733	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—DUSP6—malignant glioma	0.00315	0.00727	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCR4—malignant glioma	0.00315	0.00726	CbGpPWpGaD
Regadenoson—Urticaria—Temozolomide—malignant glioma	0.0031	0.006	CcSEcCtD
Regadenoson—Abdominal pain—Temozolomide—malignant glioma	0.00309	0.00597	CcSEcCtD
Regadenoson—Hypersensitivity—Carmustine—malignant glioma	0.00298	0.00575	CcSEcCtD
Regadenoson—Asthenia—Carmustine—malignant glioma	0.0029	0.0056	CcSEcCtD
Regadenoson—Hypersensitivity—Temozolomide—malignant glioma	0.00288	0.00556	CcSEcCtD
Regadenoson—Asthenia—Temozolomide—malignant glioma	0.0028	0.00541	CcSEcCtD
Regadenoson—Diarrhoea—Carmustine—malignant glioma	0.00277	0.00534	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—CXCR3—malignant glioma	0.00273	0.00629	CbGpPWpGaD
Regadenoson—Dizziness—Carmustine—malignant glioma	0.00267	0.00516	CcSEcCtD
Regadenoson—Diarrhoea—Temozolomide—malignant glioma	0.00267	0.00516	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—NTRK1—malignant glioma	0.00264	0.0061	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—NTRK1—malignant glioma	0.00259	0.00598	CbGpPWpGaD
Regadenoson—Dizziness—Temozolomide—malignant glioma	0.00258	0.00499	CcSEcCtD
Regadenoson—Vomiting—Carmustine—malignant glioma	0.00257	0.00497	CcSEcCtD
Regadenoson—Rash—Carmustine—malignant glioma	0.00255	0.00492	CcSEcCtD
Regadenoson—Dermatitis—Carmustine—malignant glioma	0.00255	0.00492	CcSEcCtD
Regadenoson—Headache—Carmustine—malignant glioma	0.00253	0.00489	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—BDKRB2—malignant glioma	0.0025	0.00576	CbGpPWpGaD
Regadenoson—Vomiting—Temozolomide—malignant glioma	0.00248	0.0048	CcSEcCtD
Regadenoson—Rash—Temozolomide—malignant glioma	0.00246	0.00476	CcSEcCtD
Regadenoson—Dermatitis—Temozolomide—malignant glioma	0.00246	0.00475	CcSEcCtD
Regadenoson—Headache—Temozolomide—malignant glioma	0.00245	0.00473	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—YWHAE—malignant glioma	0.00245	0.00564	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NTRK2—malignant glioma	0.00245	0.00564	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—DUSP6—malignant glioma	0.00242	0.00559	CbGpPWpGaD
Regadenoson—Nausea—Carmustine—malignant glioma	0.0024	0.00464	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—CCR4—malignant glioma	0.0024	0.00553	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCR3—malignant glioma	0.00234	0.00539	CbGpPWpGaD
Regadenoson—Nausea—Temozolomide—malignant glioma	0.00232	0.00448	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—NCOR1—malignant glioma	0.00231	0.00533	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PDGFRA—malignant glioma	0.00217	0.005	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—BDKRB2—malignant glioma	0.00214	0.00493	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LATS2—malignant glioma	0.00205	0.00472	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NTRK1—malignant glioma	0.00199	0.0046	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PDGFB—malignant glioma	0.00195	0.00449	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—KNG1—malignant glioma	0.00195	0.00449	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGFR1—malignant glioma	0.00194	0.00447	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CXCR3—malignant glioma	0.00178	0.00411	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—BAD—malignant glioma	0.00174	0.00401	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CD80—malignant glioma	0.00169	0.00389	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PDGFRA—malignant glioma	0.00167	0.00385	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGF—malignant glioma	0.00166	0.00383	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PPARG—malignant glioma	0.00166	0.00382	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTPN11—malignant glioma	0.00165	0.00381	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—BDKRB2—malignant glioma	0.00163	0.00376	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—malignant glioma	0.00158	0.00365	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LATS1—malignant glioma	0.00155	0.00358	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT2—malignant glioma	0.00154	0.00355	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PDGFB—malignant glioma	0.0015	0.00346	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—FGFR1—malignant glioma	0.00149	0.00344	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—KNG1—malignant glioma	0.00148	0.00342	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CD—malignant glioma	0.00148	0.00341	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGF2—malignant glioma	0.00142	0.00326	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CCR4—malignant glioma	0.00135	0.00312	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—BAD—malignant glioma	0.00134	0.00308	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MDM2—malignant glioma	0.00132	0.00305	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—RAF1—malignant glioma	0.00132	0.00304	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—malignant glioma	0.00131	0.00301	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CD80—malignant glioma	0.0013	0.00299	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CB—malignant glioma	0.00129	0.00297	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—EGF—malignant glioma	0.00128	0.00295	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PTPN11—malignant glioma	0.00127	0.00293	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—F2—malignant glioma	0.00126	0.0029	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCR4—malignant glioma	0.00123	0.00284	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—BRAF—malignant glioma	0.00122	0.0028	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—AKT2—malignant glioma	0.00118	0.00273	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CD—malignant glioma	0.00114	0.00262	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PTEN—malignant glioma	0.00114	0.00262	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—malignant glioma	0.00111	0.00257	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—FGF2—malignant glioma	0.00109	0.00251	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MDK—malignant glioma	0.00105	0.00242	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MDM2—malignant glioma	0.00102	0.00235	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—RAF1—malignant glioma	0.00102	0.00234	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCR3—malignant glioma	0.00101	0.00232	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—ERBB2—malignant glioma	0.001	0.00232	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—DTX1—malignant glioma	0.001	0.00231	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—malignant glioma	0.000996	0.0023	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CB—malignant glioma	0.000991	0.00229	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—F2—malignant glioma	0.000958	0.00221	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—BDKRB2—malignant glioma	0.000921	0.00212	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCR3—malignant glioma	0.000914	0.00211	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CASP3—malignant glioma	0.000912	0.0021	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—malignant glioma	0.000905	0.00209	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—malignant glioma	0.000886	0.00204	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PTEN—malignant glioma	0.000857	0.00198	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—malignant glioma	0.000855	0.00197	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—KNG1—malignant glioma	0.000838	0.00193	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—BDKRB2—malignant glioma	0.000836	0.00193	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SUFU—malignant glioma	0.000794	0.00183	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—malignant glioma	0.000786	0.00181	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HEY2—malignant glioma	0.000785	0.00181	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—TP53—malignant glioma	0.000775	0.00179	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GFAP—malignant glioma	0.000766	0.00177	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—STAT3—malignant glioma	0.000766	0.00177	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—KNG1—malignant glioma	0.000761	0.00175	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SPHK1—malignant glioma	0.000742	0.00171	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCR4—malignant glioma	0.000727	0.00168	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HEY1—malignant glioma	0.000727	0.00168	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HIST1H3B—malignant glioma	0.000706	0.00163	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—EGFR—malignant glioma	0.000696	0.00161	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CXCL8—malignant glioma	0.000675	0.00156	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MMP3—malignant glioma	0.000674	0.00155	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—KRAS—malignant glioma	0.000658	0.00152	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JAG2—malignant glioma	0.000644	0.00149	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—malignant glioma	0.000642	0.00148	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CA—malignant glioma	0.000604	0.00139	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—H3F3A—malignant glioma	0.000545	0.00126	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—F2—malignant glioma	0.000541	0.00125	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCR3—malignant glioma	0.00054	0.00125	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—YWHAE—malignant glioma	0.000525	0.00121	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NTRK2—malignant glioma	0.000525	0.00121	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FLT1—malignant glioma	0.000523	0.00121	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—DUSP6—malignant glioma	0.000521	0.0012	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CG—malignant glioma	0.000518	0.00119	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JAG1—malignant glioma	0.000514	0.00119	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOTCH3—malignant glioma	0.000512	0.00118	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FBXW7—malignant glioma	0.000504	0.00116	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BDKRB2—malignant glioma	0.000494	0.00114	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—AKT1—malignant glioma	0.000494	0.00114	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—F2—malignant glioma	0.000492	0.00113	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT2—malignant glioma	0.000474	0.00109	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CG—malignant glioma	0.00047	0.00108	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PTPN11—malignant glioma	0.000462	0.00107	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOTCH2—malignant glioma	0.000459	0.00106	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CD—malignant glioma	0.000455	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KNG1—malignant glioma	0.000449	0.00104	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT2—malignant glioma	0.00043	0.000992	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NTRK1—malignant glioma	0.000428	0.000987	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CD—malignant glioma	0.000414	0.000954	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MMP3—malignant glioma	0.000398	0.000918	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CB—malignant glioma	0.000397	0.000915	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN2B—malignant glioma	0.000395	0.00091	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTK2—malignant glioma	0.000383	0.000884	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCL8—malignant glioma	0.000381	0.00088	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HES1—malignant glioma	0.000376	0.000868	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NCOR1—malignant glioma	0.000374	0.000863	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—RAF1—malignant glioma	0.000369	0.000851	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—IL2—malignant glioma	0.000365	0.000841	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CB—malignant glioma	0.00036	0.000831	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDGFRA—malignant glioma	0.000358	0.000826	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SPP1—malignant glioma	0.000348	0.000802	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL8—malignant glioma	0.000346	0.000799	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL2—malignant glioma	0.000331	0.000763	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TERT—malignant glioma	0.00033	0.000761	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDGFB—malignant glioma	0.000322	0.000742	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGFR1—malignant glioma	0.00032	0.000738	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HIF1A—malignant glioma	0.000315	0.000727	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CAV1—malignant glioma	0.000305	0.000703	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KDR—malignant glioma	0.000302	0.000696	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—F2—malignant glioma	0.00029	0.00067	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FN1—malignant glioma	0.00029	0.00067	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BAD—malignant glioma	0.000287	0.000662	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOTCH1—malignant glioma	0.000284	0.000655	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CD80—malignant glioma	0.000278	0.000642	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CG—malignant glioma	0.000278	0.000641	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APC—malignant glioma	0.000278	0.000641	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EGF—malignant glioma	0.000275	0.000633	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTPN11—malignant glioma	0.000273	0.00063	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BRAF—malignant glioma	0.000261	0.000602	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT2—malignant glioma	0.000254	0.000586	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EGFR—malignant glioma	0.000253	0.000584	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CD—malignant glioma	0.000244	0.000563	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CA—malignant glioma	0.000242	0.000558	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—KRAS—malignant glioma	0.000239	0.000552	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGF2—malignant glioma	0.000234	0.000539	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CA—malignant glioma	0.00022	0.000507	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MDM2—malignant glioma	0.000219	0.000505	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RAF1—malignant glioma	0.000218	0.000503	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ERBB2—malignant glioma	0.000216	0.000498	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CB—malignant glioma	0.000213	0.000491	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCL8—malignant glioma	0.000205	0.000472	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT1—malignant glioma	0.000198	0.000456	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CASP3—malignant glioma	0.000196	0.000452	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL2—malignant glioma	0.000196	0.000451	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MMP9—malignant glioma	0.000185	0.000427	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTEN—malignant glioma	0.000184	0.000424	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT1—malignant glioma	0.00018	0.000414	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VEGFA—malignant glioma	0.000166	0.000383	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—STAT3—malignant glioma	0.000165	0.000379	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MYC—malignant glioma	0.000153	0.000353	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EGFR—malignant glioma	0.00015	0.000345	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KRAS—malignant glioma	0.000141	0.000326	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CA—malignant glioma	0.00013	0.000299	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TP53—malignant glioma	0.000126	0.00029	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT1—malignant glioma	0.000106	0.000245	CbGpPWpGaD
